Tissue Engineering and Regenerative Medicine - Commercializing Future Life Saver (BALS18)
|Event Date/Time: Nov 08, 2005||End Date/Time: Nov 09, 2005|
|Registration Date: Nov 07, 2005|
|Early Registration Date: Jul 25, 2005|
Tissue Engineering has an enormous potential in medicine with its ability to treat various diseases and wounds. In this pulsing and fast growing environment it is difficult for the companies to stand out and to deliver an effective business model and implement the right strategy for marketing tissue-engineered products.
This conference on "Tissue Engineering and Regenerative Medicine - Commercializing Future Life Saver" brings together speakers form leading companies worldwide to discuss the hottest issues regarding tissue engineering in connection with regulatory framework, business models and identifying what works and what doesn’t and why. Not only you will network with business men and scientists representing top international biotech companies, but you will also have the opportunity to listen to latest case studies about new products and about successful marketing strategies.
• Duncan MacKay, Head of Regulatory Affairs for TEP in Europe, Genzyme Biosurgery
• Kelvin Brockbank, President & CSO of Cell & Tissue Systmes, Inc., Vice President of Organ Recovery Systems, Inc.
• Nancy Veulemans, Head R&D and Regulatory Affairs, TiGenix
• Gareth W. Roberts, CEO, NovaThera Ltd.
• Commercialization strategies for therapeutics based on living cells
• Improving logistics in distribution and storage of TEP
• Changes in regulatory framework for TEP within EU
• Spheramine - cell therapy for Parkinson's disease, Case study about requirements and clinical program for obtaining market approval
Who should attend?
CEOs, CSOs, COOs, Chief Therapeutics Officers, Vice Presidents, Heads of R&D and Laboratories, Regulatory Affairs, Directors, Senior Managers - Commercial development, Corporate Planners